Revalesio Presents Findings on Its Lead Neuroprotective Drug Candidate

Washington State-based biotech Revalesio and its academic collaborators have developed an anti-inflammatory therapeutic that mitigates the neuroinflammatory response associated with neurodegenerative diseases. While preliminary data indicates that RSN60 is beneficial for treating Alzheimer’s and Parkinson’s Diseases, it likely holds promise for development as an ALS therapeutic as well.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail